Pleiotropic effects of HMG-CoA reductase inhibitors

被引:0
|
作者
Nikos Werner
Georg Nickenig
Ulrich Laufs
机构
[1] Medizinische Klinik und Poliklinik,
[2] Innere Medizin III,undefined
[3] Universitätskliniken des Saarlandes,undefined
[4] 66421 Homburg/Saar,undefined
[5] Germany,undefined
[6] Tel.: +49-6841/16-3000,undefined
[7] Fax: +49-6841/16-3437,undefined
[8] E-Mail: Ulrich@Laufs.com,undefined
来源
关键词
Key words HMG CoA reductase inhibitiors – hypercholesterolemia – pleiotropic effects – review;
D O I
暂无
中图分类号
学科分类号
摘要
HMG CoA reductase inhibitiors (statins) have been shown to be effective lipid lowering agents and are able to significantly reduce cardiovascular mortality and morbidity in patients at risk for cardiovascular disease. Recent clinical and experimental data suggest that the benefit of statins may extend beyond their hepatic effects on serum cholesterol levels. This review summarizes the current evidence and the molecular mechanisms of the direct effects of statins on plaque stability, inflammation, endothelial function, oxidative stress, thrombosis and stroke. Furthermore, recent data on the effects of statins on bone marrow, bone density and dementia are described. In summary, statins have emerged as a novel and powerful tool to study cardiovascular biology, including protein isoprenylation, small G protein function, leukocyte activity and endothelial progenitor cells. These pleiotropic properties of statins may have important clinical implications in addition to lowering serum cholesterol.
引用
收藏
页码:105 / 116
页数:11
相关论文
共 50 条
  • [21] Comparing HMG-CoA reductase inhibitors
    Jones, PH
    CLINICAL CARDIOLOGY, 2003, 26 (01) : I15 - I20
  • [22] HMG-COA REDUCTASE INHIBITORS AND SLEEP
    SPIELBERG, SP
    TOBERT, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (01) : 109 - 110
  • [23] Diplopia and HMG-CoA reductase inhibitors
    Fraunfelder, FW
    Fraunfelder, FT
    Edwards, R
    JOURNAL OF TOXICOLOGY-CUTANEOUS AND OCULAR TOXICOLOGY, 1999, 18 (04): : 287 - 289
  • [24] Syntheses of HMG-CoA reductase inhibitors
    Nissan Chemical Industries, Ltd, Chiba, Japan
    Yuki Gosei Kagaku Kyokaishi, 3 (186-196):
  • [25] SYNTHESES OF HMG-COA REDUCTASE INHIBITORS
    MIYACHI, N
    SUZUKI, M
    OHARA, Y
    HIYAMA, T
    JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, 1995, 53 (03) : 186 - 196
  • [26] IMIDAZOLES AS HMG-COA REDUCTASE INHIBITORS
    WAREING, JR
    LEGINUS, JM
    SCALLEN, TJ
    LINDER, J
    LEE, GT
    STABLER, R
    MARTIN, M
    WIDLER, L
    MYERS, SW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1988, 196 : 106 - MEDI
  • [27] HMG-CoA reductase inhibitors and myotoxicity
    Ucar, M
    Mjörndal, T
    Dahlqvist, R
    DRUG SAFETY, 2000, 22 (06) : 441 - 457
  • [28] Rhabdomyolysis and HMG-CoA reductase inhibitors
    Omar, MA
    Wilson, JP
    Cox, TS
    ANNALS OF PHARMACOTHERAPY, 2001, 35 (09) : 1096 - 1107
  • [29] HMG-CoA Reductase Inhibitors and Myotoxicity
    Memduh Ucar
    Tom Mjörndal
    Rune Dahlqvist
    Drug Safety, 2000, 22 : 441 - 457
  • [30] HMG-CoA reductase inhibitors and the kidney
    Campese, VA
    Hadaya, B
    Chiu, J
    CURRENT HYPERTENSION REPORTS, 2005, 7 (05) : 337 - 342